Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells

about

Expression of Vascular Endothelial-Cadherin in Mucoepidermoid Carcinoma: Role in Cancer Development.

P2860

Q49529420-6EACB039-C118-40AF-A56A-FBAD7650EB6F

P2860

Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells

Item

http://www.wikidata.org/entity/Q36065121

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Epidermal Growth Factor Recept ...... adherin-5 in Lung Cancer Cells

@ast

Epidermal Growth Factor Recept ...... adherin-5 in Lung Cancer Cells

@en

type

Item

label

Epidermal Growth Factor Recept ...... adherin-5 in Lung Cancer Cells

@ast

Epidermal Growth Factor Recept ...... adherin-5 in Lung Cancer Cells

@en

prefLabel

Epidermal Growth Factor Recept ...... adherin-5 in Lung Cancer Cells

@ast

Epidermal Growth Factor Recept ...... adherin-5 in Lung Cancer Cells

@en

P1476

Epidermal Growth Factor Recept ...... adherin-5 in Lung Cancer Cells

@en

P2093

Jr-Hau Lung

http://www.w3.org/2001/XMLSchema#string

Ming-Szu Hung

http://www.w3.org/2001/XMLSchema#string

Paul-Yann Lin

http://www.w3.org/2001/XMLSchema#string

Ya-Chin Li

http://www.w3.org/2001/XMLSchema#string

Ying-Huang Tsai

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.

P304

e0158395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0158395

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

I-Chuan Chen

P577

2016-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27362942

http://www.w3.org/2001/XMLSchema#string

P932

4928829

http://www.w3.org/2001/XMLSchema#string

Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells

about

P2860

P2860

Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932